Related Experiment Video

Updated: May 8, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Targeting the ERBB family in cancer: couples therapy

Niall Tebbutt1, Mikkel W Pedersen, Terrance G Johns

  • 1Ludwig Oncology Unit, Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia.

Nature Reviews. Cancer
|August 17, 2013
PubMed

Insights

Dual-targeting therapies inhibiting ERBB family members, like epidermal growth factor receptor (EGFR) and ERBB2, show higher antitumor activity than single agents. This review covers their performance, mechanisms, and future research directions.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The ERBB family of receptor tyrosine kinases is crucial in solid tumor development.
  • Approved therapeutics targeting ERBB receptors are used in cancer treatment.

Purpose of the Study:

  • To review preclinical and clinical data on dual-targeting strategies for ERBB family members.
  • To discuss mechanisms underlying the enhanced efficacy of dual-targeting approaches.
  • To identify areas for future investigation in ERBB-targeted cancer therapy.

Main Methods:

  • Review of preclinical data on dual-targeting agents.
  • Analysis of clinical trial outcomes for dual-targeting therapies.
  • Discussion of mechanistic studies on ERBB pathway inhibition.

Main Results:

  • Dual inhibition of ERBB family members, especially EGFR and ERBB2, demonstrates superior antitumor activity compared to single-agent therapies.
  • Preclinical evidence strongly supports the increased efficacy of combining two inhibitors against a single ERBB member.
  • Clinical performance data for these dual-targeting approaches are being evaluated.

Conclusions:

  • Dual-targeting strategies represent a promising advancement in ERBB-targeted cancer therapy.
  • Understanding the mechanisms of enhanced efficacy is key to optimizing treatment.
  • Further research is needed to fully elucidate the potential and challenges of these approaches.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...